Pharmaceutical manufacturers walk a tightrope as they balance contradictory forces and changing conditions: they must meet new regulations but also need to increase outsourcing; they face expiring patents but also the expectation of sustained profitability.
The rules imposed on the industry are getting ever more complicated and represent just one of many forces eating away at bottom lines. As brands go off-patent, pharma companies increasingly rely on outsourced APIs and the expansion into emerging markets to maintain or grow revenue. That increased reliance on outside manufacturers represents a loss of control, however – a concept that runs counter to tightening regulation.
Industry leaders are shifting away from R&D and beginning to look more like the consumer packaged goods industry – they are becoming brand companies
In the past decade, the industry has witnessed an evolution, in which industry leaders are shifting away from R&D and beginning to look more like the consumer packaged goods industry – they are becoming brand companies.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.